论文部分内容阅读
目的:探讨阿托伐他汀钙片治疗慢性阻塞性肺疾病(COPD)的效果。方法:选取COPD患者150例,随机分为观察组与对照组各75例。两组给予常规治疗(如吸氧、雾化吸入、抗感染等);观察组在平常的情况下,睡前应每天服用20 mg的阿托伐他汀钙片,1个疗程是1年的时间。观察组和对照组在治疗之前与治疗第3、6、12个月后进行第1秒用力呼气容积(FEV1)、平均肺动脉压,6 min步行试验测定步行距离以及圣乔治呼吸问卷评分调查等对比。结果:观察组和对照组在治疗3个月、6个月、12个月时FEV1、6 min步行距离和平均肺动脉压以及圣乔治呼吸问卷评分对比之前的治疗有了很大的改善,且对照组的改善程度明显低于观察组,组间比较,差异具有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:COPD患者在常规治疗的基础上口服阿托伐他汀钙片具有较好疗效。
Objective: To investigate the effect of atorvastatin calcium on chronic obstructive pulmonary disease (COPD). Methods: 150 COPD patients were randomly divided into observation group and control group, 75 cases each. The two groups were given routine treatment (such as oxygen, inhalation, anti-infection, etc.); observation group under normal circumstances, should take 20 mg of atorvastatin calcium tablets daily before going to bed, a course of treatment is 1 year . Observation group and control group before treatment and the first 3,6,12 months after treatment, forced expiratory volume 1 second (FEV1), mean pulmonary artery pressure, walking distance 6min walk test and St. George’s Respiratory Questionnaire score survey Compared. Results: The observation group and the control group had a great improvement in the walking distance, mean pulmonary artery pressure, and St. George’s Respiratory Questionnaire score at 3, 6 and 12 months after treatment, and the control The improvement rate of the two groups was significantly lower than that of the observation group. There was a significant difference between the two groups (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions: COPD patients have a good effect of oral administration of atorvastatin calcium tablets on the basis of conventional treatment.